

10/594413

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

PALERMO ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP2005/003619

FILED: 6 APRIL 2005

U.S. APPLICATION NO:

35 USC §371 DATE:

FOR: INHIBITORS OF IAP

MS: Amendment

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report. Since these references are of record in the instant PCT application PCT/EP2005/003619, copies are not enclosed herewith.

10/594413

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7898


Lydia T. McNally
Attorney for Applicants
Reg. No. 36,214

Date: *Sept 26, 2006*

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

IAP18 Rec'd PCT/PTO 26 SEP 2006
ATTY. DOCKET NO.
33727-US-PCT
APPLICATION NO. 10/594413APPLICANT
PALERMO ET AL.
FILING DATE

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	WO 2004/005248	1/15/04	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AN	WO 01/90070	11/29/01	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Arnt et al., "Synthetic SMAC/Diablo peptides enhance the effects of chemotherapeutic agents by binding XIAP and CIAP1 in situ," Journal of Biological Chemistry, Vol. 277(46), pp. 44236-44243 (2002)
	AS	Kipp et al., "Molecular targeting of inhibitor of apoptosis based on small molecule mimics of natural binding partners," Biochemistry, Vol. 41(23), pp. 7344-7349 (2002)
	AT	Wu et al., "Structural analysis of a functional DIAP1 fragment bound to grim and hid peptides," Molecular Cell, Vol. 8(1), pp. 95-104 (2001)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
33727-US-PCT
APPLICATION NO.APPLICANT
PALERMO ET AL.
FILING DATE10/594413
Group
AP18 Rec'd PCT/PTO 26 SEP 2006

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						
	BL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	BM						<input type="checkbox"/>	<input type="checkbox"/>
	BN						<input type="checkbox"/>	<input type="checkbox"/>
	BO						<input type="checkbox"/>	<input type="checkbox"/>
	BP						<input type="checkbox"/>	<input type="checkbox"/>
	BQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	BR	Deal et al., "Conformationally constrained tachykinin analogues: potent and highly selective neurokinin NK-2-receptor antagonists," Journal of Medicinal Chemistry, Vol. 35(22), pp. 4195-4204 (1992)
	BS	
	BT	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.